Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response

References

• Malcovati L, Nimer SD. Myelodysplastic syndromes: diagnosis and staging. Cancer Control 2008;15(Suppl.):4-13
   PubMedGoogle Scholar
• Jadersten M, Hellstrom-Lindberg E. Myelodysplastic syndromes: biology and treatment. J Intern Med 2009;265:307-28
   PubMed Web of Science ®Google Scholar
• Cazzola M, Malcovati L. Myelodysplastic syndromes – coping with ineffective hematopoiesis. N Engl J Med 2005;352:536-8
   PubMed Web of Science ®Google Scholar
• Kouides PA, Bennett JM. Understanding the myelodysplastic syndromes. Oncologist 1997;2:389-401
   PubMedGoogle Scholar
• Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues: International Agency for Research on Cancer (IARC), 2008
   Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-10
   PubMed Web of Science ®Google Scholar
• Littlewood TJ. Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematol Oncol 2001;19:19-30
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-49
   PubMed Web of Science ®Google Scholar
• Stein RS, Abels RI, Krantz SB. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 1991;78:1658-63
   PubMed Web of Science ®Google Scholar
• A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 1998;103:1070-4
   PubMedGoogle Scholar
• Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998;92:68-75
   PubMed Web of Science ®Google Scholar
• Mannone L, Gardin C, Quarre MC, et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 2006;133:513-19
   PubMed Web of Science ®Google Scholar
• Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005;128:204-9
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-76
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20
   PubMed Web of Science ®Google Scholar
• Hedenus M, Hansen S, Taylor K, et al. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002;119:79-86
   PubMed Web of Science ®Google Scholar
• Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-34
   PubMed Web of Science ®Google Scholar
• Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84(Suppl. 1):3-10
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Fu AZ, Maciejewski JP, et al. A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Cancer 2007;109:1125-32
   PubMed Web of Science ®Google Scholar
• Rose EH, Abels RI, Nelson RA, et al. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 1995;89:831-7
   PubMed Web of Science ®Google Scholar
• Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008;111:574-82
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997;99:344-51
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-4
   PubMed Web of Science ®Google Scholar
• Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manag 2002;24:547-61
   PubMed Web of Science ®Google Scholar
• Stasi R, Pagano A, Terzoli E, et al. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. Br J Haematol 1999;105:141-8
   PubMed Web of Science ®Google Scholar
• Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996;87:4076-81
   PubMed Web of Science ®Google Scholar
• Koury MJ, Bondurant MC. The molecular mechanism of erythropoietin action. Eur J Biochem 1992;210:649-63
   PubMedGoogle Scholar
• Backx B, Broeders L, Hoefsloot LH, et al. Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand. Leukemia 1996;10:466-72
   PubMed Web of Science ®Google Scholar
• Hoefsloot LH, van Amelsvoort MP, Broeders LC, et al. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood 1997;89:1690-700
   PubMed Web of Science ®Google Scholar
• Rigolin GM, Porta MD, Bigoni R, et al. rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors’ response by fluorescence in situ hybridization on May–Grunwald–Giemsa-stained bone marrow samples. Br J Haematol 2002;119:652-9
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:67-71
   PubMed Web of Science ®Google Scholar
• Terpos E, Mougiou A, Kouraklis A, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002;118:174-80
   PubMed Web of Science ®Google Scholar
• Remacha AF, Arrizabalaga B, Villegas A, et al. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica 1999;84:1058-64
   Google Scholar
• Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004;104:321-7
   PubMed Web of Science ®Google Scholar
• Mantovani L, Lentini G, Hentschel B, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 2000;109:367-75
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:1037-46
   PubMed Web of Science ®Google Scholar
• Gabrilove J, Paquette R, Lyons RM, et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008;142:379-93
   PubMed Web of Science ®Google Scholar
• Stasi R, Abruzzese E, Lanzetta G, et al. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005;16:1921-7
   PubMed Web of Science ®Google Scholar
• Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403
   PubMed Web of Science ®Google Scholar
• Ross SD, Allen IE, Probst CA, et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 2007;12:1264-73
   PubMed Web of Science ®Google Scholar
• Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008;87:527-36
   PubMed Web of Science ®Google Scholar
• Mundle S, Lefebvre P, Vekeman F, et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 2009;115:706-15
   PubMed Web of Science ®Google Scholar